Antiplatelet therapy in secondary stroke prevention

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 10, 2001, Pages 1609-1613

  Crawford, M K ^a   Talbert, R L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antiplatelet; Aspirin; Clopidogrel; Dipyridamole; Stroke prevention; Thienopyridine ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; LOTRAFIBAN; PLACEBO; PYRIDINE DERIVATIVE; SIBRAFIBAN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; UNCLASSIFIED DRUG; WARFARIN;

CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG COST; DRUG INDICATION; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; NEUTROPENIA; RASH; REVIEW; STROKE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT PLANNING; UNITED STATES;

ASPIRIN; CEREBROVASCULAR ACCIDENT; DIPYRIDAMOLE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0034757474     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.10.1609     Document Type: Review

References (36)

1. Deaths: Final data for 1996
2. The greater Cincinnati/northern Kentucky stroke study: Preliminary first-ever and total incidence rates of stroke among blacks
3. Cost of stroke
4. Disease and injury in California with projections to the year 2007. Implications for medical education
5. Declining trends in incidence, case-fatality and mortality of stroke in three geographic areas of Finland during 1983-1989. Results from the FINMONICA stroke register
6. Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA project. An ecological study of 18 populations
7. Widening gap of stroke between east and west. Eight-year trends in occurrence and risk factors in Russia and Sweden
8. 2001 Heart and stroke statistical update
9. Cerebrovascular diseases
10. Aspirin use and incident stroke in the Cardiovascular Health Study
11. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
12. Swedish aspirin low-dose trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
13. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke
14. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial
15. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products
16. Antithrombotic and thrombolytic therapy for ischemic stroke
17. Atrial fibrillation and stroke
18. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation
19. 3H]-2-methylthio ADP to rat platelets-effect of clopidogrel and ticlopidine
20. Prevention of stroke with ticlopidine: Who benefits most?
21. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke
22. The antiplatelet effects of ticlopidine and clopidogrel
23. Thrombotic thrombocytopenic purpura associated with ticlopidine use: A report of 3 cases and review of the literature
24. The efficacy and safety of ticlopidine and aspirin in non-whites: Analysis of a patient subgroup from the Ticlopidine and Aspirin Stroke Study
25. Caprie Steering Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE)
26. Thrombotic thrombocytopenic purpura associated with clopidogrel
27. Pharmacology of current and future antithrombotic therapies
28. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin
29. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke: European Stroke Prevention Study 2
30. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
31. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists
32. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors
33. Design of the blockade of the glycoprotein Iib/IIIa receptor to avoid vascular occluion (BRAVO) trial
34. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin after coronary stenting
35. Future perspectives for optimizing oral antiplatelet therapy
36. Benefit of ADP receptor antagonists in atherotrhombotic patients: New evidence